All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a healthcare professional. If you are a patient or carer, please visit Know ALL.
The ALL Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the ALL Hub cannot guarantee the accuracy of translated content. The ALL Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
The ALL Hub is an independent medical education platform, sponsored by Amgen and Autolus. Funders are allowed no direct influence on our content. The levels of sponsorship listed are reflective of the amount of funding given. View funders.
Now you can support HCPs in making informed decisions for their patients
Your contribution helps us continuously deliver expertly curated content to HCPs worldwide. You will also have the opportunity to make a content suggestion for consideration and receive updates on the impact contributions are making to our content.
Find out more
Create an account to access:
Bookmark & personalize site content
Receive alerts for new content in your areas of interest
View ALL content recommended for you
US consensus recommendations on optimizing asparaginase-based therapy for patients with acute lymphoblastic leukemia (ALL) / lymphoblastic lymphoma (LBL) were published in the American Journal of Hematology by Ali et al. Building on previous US consensus recommendations for adolescent and young adult (AYA) patients, the expanded guidance addresses specialist care teams and infrastructure, patient navigation throughout the treatment journey, and practical strategies for healthcare professionals to optimize asparaginase delivery and treatment completion.
Key data: Recommendations include establishing multidisciplinary care teams at specialized centers, with defined team roles and shared-care pathways, where infrastructure permits. Patients should have access to supportive care professionals and be screened for psychosocial distress at diagnosis and at each encounter. Structured patient education and adherence support should be provided throughout treatment, including guidance on potential toxicities, dosing schedules, and the importance of completing planned asparaginase doses. Age-appropriate patients should be referred at diagnosis to centers experienced in pediatric-inspired regimens. Therapeutic drug monitoring (TDM)-guided protocols should be integrated into routine care to detect silent asparaginase inactivation,particularly with long-acting formulations. Patients experiencing hypersensitivity reactions or silent inactivation with E. coli-derived asparaginase should be switched to recombinant Erwinia asparaginase within 48 to 72 hours, or as soon as feasible.
Key learning: These consensus recommendations outline specific, actionable guidance to optimize asparaginase-based therapy in patients with ALL/LBL.
References
Please indicate your level of agreement with the following statements:
The content was clear and easy to understand
The content addressed the learning objectives
The content was relevant to my practice
I will change my clinical practice as a result of this content
This content is accurate as of the date of publication and is not updated retrospectively. Please refer to the latest available evidence, guidelines, and relevant regulatory information when making clinical decisions.